Shenzhen Kangzhe, a Subsidiary of China Medical System (867.HK), Again Listed in “Shenzhen Top 500 Enterprises”

Company News

On September 21, Shenzhen Enterprise Federation and Shenzhen Enterprise Directors Association released the list of “2022 Shenzhen Top 500 Enterprises”. With outstanding performance in terms of business scale, employees scale, tax payment, social responsibility, etc., Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 130.

As a local enterprise born and grown in Shenzhen, Shenzhen Kangzhe capitalizes on the global upstream and downstream resources accumulated by the Group to fulfill the mission of “Providing competitive products and services to meet unmet healthcare and aesthetic needs” and benefit more patients with accessible and affordable quality medicines. Being once again selected for the “Shenzhen Top 500 Enterprises” shows the recognition of Shenzhen Kangzhe’s comprehensive strength and brand value. In the future, CMS will continue to proactively seize the opportunities presented by the construction of the Guangdong-Hong Kong-Macao Greater Bay Area and the Pioneering Demonstration Zone of Socialism with Chinese Characteristics, as well as the Shenzhen Comprehensive Reform Zone and the Reform and Opening Up of Qianhai Cooperation Zone, empower innovation and foster bio-technology transformation, making positive contributions to the development of Shenzhen’s biopharmaceutical industry.